分散式臨床試驗市場－全球產業規模、佔有率、趨勢、機會及預測（依研究設計、治療領域、最終用戶、地區及競爭格局分類，2021-2031年）

全球分散式臨床試驗 (DCT) 市場預計將從 2025 年的 104.6 億美元大幅成長至 2031 年的 232.4 億美元，複合年成長率達 14.23%。

分散式臨床試驗是一種研究執行模式，在這種模式下，研究活動透過遠端方式進行，利用遠距遠端醫療、行動醫療服務和數位資料收集工具，有效降低了對實體研究中心的依賴。這個市場的主要驅動力在於：克服地域限制以增加患者多樣性；透過提高便利性來提升參與者的留存率；以及為支持這種以患者為中心的研究方法，對持續收集真實世界數據的需求日益成長。

然而，儘管這些優勢顯而易見，但市場擴張的一大障礙是研究中心面臨的營運複雜性和管理負擔。數位平台固有的片段化常常迫使研究中心工作人員在多個互不相連的系統間切換，導致工作流程效率低下，並增加了訓練需求。根據臨床研究專業人員協會 (ACRP) 預測，到 2024 年，38% 的臨床研究中心將把日益複雜的臨床試驗列為一項主要的營運挑戰，這凸顯了將這些遠端技術整合到標準作業流程中的巨大困難。

市場促進因素

患者族群多樣化和招募效率的提高是全球分散式臨床試驗 (DCT) 市場的主要促進因素。透過利用遠端監測和本地醫療服務提供者，DCT 消除了以往將某些人群排除在外的地理障礙，使申辦方能夠接觸到更廣泛、更具代表性的目標人群。近期行業數據也支持了這一轉變，這些數據表明分散式方法在覆蓋代表性不足的群體方面卓有成效。例如，塔夫茨藥物研發研究中心 (Tufts Center for the Study of Drug Development) 於 2025 年 1 月發布的分析報告《分散化對臨床試驗績效的影響》發現，分散式試驗中亞洲受試者的比例達到了 20.9%，較傳統中心式試驗的 14.2% 有了顯著提高。

同時，以患者為中心的試驗模式日益普及，正在創造一個以參與者便利性和參與度為優先的市場格局。隨著試驗通訊協定的要求越來越高，相關人員正在利用數位化工具來減輕病患負擔，並確保他們能夠持續參與整個試驗過程。根據Greenphire於2024年10月發布的《2024年市場洞察調查》，97%的臨床研究機構強調，對參與者而言，使用者友善的技術是試驗成功的關鍵因素。隨著整個行業營運瓶頸的日益增多，這種對用戶友善性和效率的追求至關重要。 WCG Clinical的《2024年報告》顯示，35%的研究機構認為研究啟動準備是他們面臨的最大營運挑戰，這凸顯了提高效率和以患者為中心的執行策略的迫切需求。

市場挑戰

營運複雜性和研究中心面臨的行政負擔是限制全球分散式臨床試驗 (DCT) 市場成長的重要瓶頸。儘管分散式模式旨在減輕患者的負擔，但實際上，它往往將物流負擔轉移到研究中心工作人員身上，他們必須應對分散的技術環境。每個研究都需要管理多個獨立的登入帳號、培訓模組和資料介面，這造成了嚴重的工作流程效率低下。當研究中心負責人被迫花費更多時間處理非臨床行政任務時，其啟動和維護新研究的能力就會下降，這直接導致分散式試驗的成功率降低。

這種對設施資源的壓力對支撐市場成長的研究基礎設施的財務和營運永續性產生了嚴重影響。當設施無法收回與這些效率低下相關的成本時，它們往往不願意採用分散式通訊協定。根據臨床研究機構協會 (SCRS) 預測，到 2024 年，50% 的臨床研究機構將面臨營運資金少於三個月的情況。這種財務脆弱性部分源自於管理複雜遠端技術所帶來的無償資源消耗，迫使許多機構放棄分散式試驗，從而限制了市場的擴充性和整體覆蓋範圍。

市場趨勢

由於對高度精確和客觀的生理終點指標的需求日益成長，透過醫用級穿戴式設備進行連續遠端監測正迅速從輔助性新技術發展成為研究通訊協定的核心組成部分。這一趨勢標誌著研究方法從間歇性資料收集到持續性資料收集的重要轉變，使申辦者能夠獲取縱向健康指標，例如生命徵象和睡眠模式，而無需受試者頻繁往返診所。使用者的高度參與日益證明了該技術的實用性，並緩解了人們對遠端環境通訊協定依從性的擔憂。根據臨床研究專業人員協會 (ACRP) 於 2024 年 10 月發表的報導《利用穿戴式數位健康科技增強臨床試驗》，多項使用穿戴式裝置的研究表明，病患依從率高達 70% 至 80%，證實了其在支持嚴謹的分散式調查方法的有效性。

同時，人工智慧 (AI) 在預測性患者招募方面的應用，正從根本上改變著申辦者識別和招募合格研究人群的方式。透過應用先進的機器學習演算法，相關人員可以分析大量資料集，精準識別合適的候選人，從而降低傳統入組策略中普遍存在的高失敗率。隨著企業尋求最佳化資源配置並加快研究進程，這項技術的應用正從實驗性試點走向廣泛應用。根據皮斯托亞聯盟 (Pistoia Alliance) 於 2024 年 9 月開展的“2024 年未來實驗室全球調查”，目前 68% 的生命科學專業人士在其工作​​中運用人工智慧和機器學習技術，上年度的54% 顯著成長。這項結果凸顯了這些工具在研究工作流程中的快速普及。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球分散式臨床試驗（DCT）市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依研究設計（介入試驗、觀察性研究、擴大使用試驗）
  • 依治療領域（腫瘤學、心血管疾病、感染疾病、代謝性疾病、神經病學、免疫學、呼吸系統疾病、其他）
  • 按最終用戶（製藥/生物技術公司、合約研究組織 (CRO)、學術/研究機構、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美分散式臨床試驗（DCT）市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲分散式臨床試驗 (DCT) 市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區分散式臨床試驗（DCT）市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲分散式臨床試驗 (DCT) 市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲分散式臨床試驗（DCT）市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球分散式臨床試驗（DCT）市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• IQVIA Inc.
• Thermo Fisher Scientific Inc.
• Laboratory Corporation of America Holdings
• ICON plc
• Clario
• Science 37, Inc.
• Parexel International Corporation
• Obvio Health USA, Inc.
• Signant Health
• Reify Health, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Decentralized Clinical Trials (DCTs) Market is projected to experience substantial growth, rising from a valuation of USD 10.46 Billion in 2025 to USD 23.24 Billion by 2031, reflecting a CAGR of 14.23%. Decentralized Clinical Trials represent a research execution model that leverages telemedicine, mobile healthcare services, and digital data acquisition tools to conduct study activities remotely, effectively reducing the dependence on physical investigative sites. The market is primarily driven by the necessity to enhance patient diversity by overcoming geographic limitations and the need to improve participant retention through increased convenience, alongside a growing demand for continuous, real-world data collection that supports these patient-focused methodologies.

However, despite these evident benefits, a major obstacle hindering market expansion is the operational complexity and administrative strain placed on investigative sites. The fragmentation inherent in digital platforms frequently compels site staff to navigate multiple unconnected systems, resulting in workflow inefficiencies and heightened training demands. According to the Association of Clinical Research Professionals, in 2024, 38% of clinical research sites cited the increasing complexity of clinical trials as their primary operational challenge, underscoring the significant difficulties associated with integrating these remote technologies into standard practice.

Market Driver

The imperative to improve patient diversity and recruitment efficiency serves as a primary catalyst for the Global Decentralized Clinical Trials (DCTs) Market. By utilizing remote monitoring and local healthcare providers, DCTs dismantle the geographic barriers that have historically excluded specific demographics, enabling sponsors to access a wider and more representative population. This shift is substantiated by recent industry data showing the effectiveness of decentralized methods in reaching underrepresented groups; for instance, the Tufts Center for the Study of Drug Development's January 2025 analysis, 'Impact of Decentralization on Clinical Trial Performance,' revealed that decentralized trials achieved an Asian participant representation of 20.9%, a marked improvement over the 14.2% seen in traditional site-based studies.

Concurrently, the increasing adoption of patient-centric trial models is transforming the market landscape by prioritizing participant convenience and retention. As protocols become more demanding, stakeholders are employing digital tools to alleviate the burden on patients, thereby ensuring sustained engagement throughout the study. According to Greenphire's '2024 Market Trends Survey' from October 2024, 97% of clinical research sites emphasized the importance of ease-of-use technology for participants as a critical factor for trial success. This push for user-friendly efficiency is vital given the broader operational bottlenecks in the industry; WCG Clinical reported in 2024 that 35% of research sites identified study start-up as their top operational challenge, highlighting the urgent demand for streamlined, patient-first execution strategies.

Market Challenge

The operational complexity and administrative burden placed on investigative sites constitute a critical bottleneck restricting the growth of the Global Decentralized Clinical Trials (DCTs) Market. While the decentralized model is designed to alleviate patient burden, it often transfers the logistical weight to site staff who must navigate a fragmented landscape of disparate technologies. The requirement to manage multiple unique logins, training modules, and data interfaces for each study creates significant workflow inefficiencies. As site personnel are compelled to divert increasing amounts of time toward non-clinical administrative tasks, their operational capacity to initiate and maintain new trials diminishes, directly reducing the volume of decentralized studies that can be successfully executed.

This strain on site resources severely impacts the financial and operational sustainability of the research infrastructure necessary to support market growth. When sites are unable to recover the costs associated with these inefficiencies, they become reluctant to adopt decentralized protocols. According to the Society for Clinical Research Sites, in 2024, 50% of clinical research sites reported having three months or less of operating capital. This financial fragility, driven in part by the uncompensated resource drain of managing complex remote technologies, forces many sites to decline participation in decentralized trials, thereby limiting the market's scalability and overall reach.

Market Trends

The integration of Medical-Grade Wearables for Continuous Remote Monitoring is rapidly evolving from a supplementary novelty to a central component of study protocols, driven by the need for high-fidelity, objective physiological endpoints. This trend signifies a critical shift away from episodic data collection, allowing sponsors to capture longitudinal health metrics such as vital signs and sleep patterns without burdening participants with frequent on-site visits. The operational viability of this technology is increasingly validated by strong user engagement, which mitigates concerns regarding protocol compliance in a remote setting; according to the Association of Clinical Research Professionals' October 2024 article, 'Enhancing Clinical Trials with Wearable Digital Health Technologies,' multiple studies utilizing wearable devices demonstrated high patient adherence rates between 70% and 80%, confirming their effectiveness in supporting rigorous decentralized methodologies.

Simultaneously, the adoption of Artificial Intelligence for Predictive Patient Recruitment is fundamentally altering how sponsors identify and engage eligible study populations. By deploying advanced machine learning algorithms, stakeholders can now analyze vast datasets to precisely target suitable candidates, thereby reducing the high failure rates associated with traditional enrollment strategies. This technological integration has transitioned from experimental pilots to widespread operational usage as companies seek to optimize resource allocation and accelerate trial timelines. According to the Pistoia Alliance's September 2024 'Lab of the Future 2024 Global Survey,' 68% of life science professionals reported currently using Artificial Intelligence and Machine Learning in their work, a significant increase from 54% in the previous year that highlights the rapid entrenchment of these tools in research workflows.

Key Market Players

• IQVIA Inc.
• Thermo Fisher Scientific Inc.
• Laboratory Corporation of America Holdings
• ICON plc
• Clario
• Science 37, Inc.
• Parexel International Corporation
• Obvio Health USA, Inc.
• Signant Health
• Reify Health, Inc.

Report Scope

In this report, the Global Decentralized Clinical Trials (DCTs) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Decentralized Clinical Trials (DCTs) Market, By Study Design

• Interventional Trials
• Observational Studies
• Expanded Access Trials

Decentralized Clinical Trials (DCTs) Market, By Therapeutic Area

• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Metabolic Disorders
• Neurology
• Immunology
• Respiratory Diseases
• Others

Decentralized Clinical Trials (DCTs) Market, By End User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutions
• Others

Decentralized Clinical Trials (DCTs) Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Decentralized Clinical Trials (DCTs) Market.

Available Customizations:

Global Decentralized Clinical Trials (DCTs) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Decentralized Clinical Trials (DCTs) Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Study Design (Interventional Trials, Observational Studies, Expanded Access Trials)
  • 5.2.2. By Therapeutic Area (Oncology, Cardiovascular Diseases, Infectious Diseases, Metabolic Disorders, Neurology, Immunology, Respiratory Diseases, Others)
  • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutions, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Decentralized Clinical Trials (DCTs) Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Study Design
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Decentralized Clinical Trials (DCTs) Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Study Design
      • 6.3.1.2.2. By Therapeutic Area
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Decentralized Clinical Trials (DCTs) Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Study Design
      • 6.3.2.2.2. By Therapeutic Area
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Decentralized Clinical Trials (DCTs) Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Study Design
      • 6.3.3.2.2. By Therapeutic Area
      • 6.3.3.2.3. By End User

7. Europe Decentralized Clinical Trials (DCTs) Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Study Design
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Decentralized Clinical Trials (DCTs) Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Study Design
      • 7.3.1.2.2. By Therapeutic Area
      • 7.3.1.2.3. By End User
  • 7.3.2. France Decentralized Clinical Trials (DCTs) Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Study Design
      • 7.3.2.2.2. By Therapeutic Area
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Decentralized Clinical Trials (DCTs) Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Study Design
      • 7.3.3.2.2. By Therapeutic Area
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Decentralized Clinical Trials (DCTs) Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Study Design
      • 7.3.4.2.2. By Therapeutic Area
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Decentralized Clinical Trials (DCTs) Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Study Design
      • 7.3.5.2.2. By Therapeutic Area
      • 7.3.5.2.3. By End User

8. Asia Pacific Decentralized Clinical Trials (DCTs) Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Study Design
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Decentralized Clinical Trials (DCTs) Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Study Design
      • 8.3.1.2.2. By Therapeutic Area
      • 8.3.1.2.3. By End User
  • 8.3.2. India Decentralized Clinical Trials (DCTs) Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Study Design
      • 8.3.2.2.2. By Therapeutic Area
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Decentralized Clinical Trials (DCTs) Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Study Design
      • 8.3.3.2.2. By Therapeutic Area
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Decentralized Clinical Trials (DCTs) Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Study Design
      • 8.3.4.2.2. By Therapeutic Area
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Decentralized Clinical Trials (DCTs) Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Study Design
      • 8.3.5.2.2. By Therapeutic Area
      • 8.3.5.2.3. By End User

9. Middle East & Africa Decentralized Clinical Trials (DCTs) Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Study Design
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Decentralized Clinical Trials (DCTs) Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Study Design
      • 9.3.1.2.2. By Therapeutic Area
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Decentralized Clinical Trials (DCTs) Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Study Design
      • 9.3.2.2.2. By Therapeutic Area
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Decentralized Clinical Trials (DCTs) Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Study Design
      • 9.3.3.2.2. By Therapeutic Area
      • 9.3.3.2.3. By End User

10. South America Decentralized Clinical Trials (DCTs) Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Study Design
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Decentralized Clinical Trials (DCTs) Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Study Design
      • 10.3.1.2.2. By Therapeutic Area
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Decentralized Clinical Trials (DCTs) Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Study Design
      • 10.3.2.2.2. By Therapeutic Area
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Decentralized Clinical Trials (DCTs) Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Study Design
      • 10.3.3.2.2. By Therapeutic Area
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Decentralized Clinical Trials (DCTs) Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. IQVIA Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific Inc.
• 15.3. Laboratory Corporation of America Holdings
• 15.4. ICON plc
• 15.5. Clario
• 15.6. Science 37, Inc.
• 15.7. Parexel International Corporation
• 15.8. Obvio Health USA, Inc.
• 15.9. Signant Health
• 15.10. Reify Health, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer